Antiangiogenesis, heralded a while ago as the "magic bullet" to stop cancer growth, has lately entered a reconsideration phase. Results obtained in phase 1 through 3 clinical trials with different ...
One of the first antiangiogenesis compounds to be proposed and evaluated for treatment of patients with cancer was endostatin, a 20-KD proteolytic fragment of collagen XVIII, which inhibits ...